{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T12:38:23Z","timestamp":1785242303701,"version":"3.55.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) and erectile dysfunction are common disorders of advancing age.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of tamsulosin and tadalafil in patients with LUTS due to BPH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective randomized study, 133 men complaining of LUTS due to BPH were included. Forty-five patients received tamsulosin 0.4 mg\/day alone (Group A), 44 patients received tadalafil 10 mg\/day (Group B), and combination therapy (tamsulosin and tadalafil both) was instituted in 44 patients (Group C). After a 2-week medication free run-in period, they were evaluated for International Prostatic Symptom Score (IPSS), International Index of Erectile Function score (IIEF5), quality of life (IPSS QoL), maximum urinary flow rate (Qmax), post-void residual urine (PVR) volume, and safety parameters before and at 3 months of treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main Outcome Measures<\/jats:title>\n                    <jats:p>There were primary (IPSS, IPSS QoL index, Qmax, and PVR) and secondary (erectile function [EF] domain scores from IIEF5) efficacy end points. Safety assessment included laboratory tests and patient's reporting of adverse event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A significant improvement in IPSS score was observed in all the 3 groups A, B, and C (\u221250.90%, P &amp;lt; 0.05; \u221233.50%, P &amp;lt; 0.05; and \u221253.90%, P &amp;lt; 0.05, respectively). IIEF5 score increased significantly in these three groups (+39.28%, P &amp;lt; 0.05; +45.96%, P &amp;lt; 0.05; and +60.23%, P &amp;lt; 0.05, respectively). A significant increase in Qmax and decrease in PVR were also observed (33.99%, P &amp;lt; 0.05; 29.78%, P &amp;lt; 0.05; and 37.04%, P &amp;lt; 0.05) and (\u221260.90%, P &amp;lt; 0.05; \u221249.45%, P &amp;lt; 0.05; and \u221262.97%, P &amp;lt; 0.05, respectively). The QoL scores improved significantly (\u221273.35%, P &amp;lt; 0.05; \u221270.26%, P &amp;lt; 0.05; and \u221279.65%, P &amp;lt; 0.05, respectively). Side effects were dyspepsia, heartburn, headache, flushing, myalgia, and backache. Adverse effect dropout was 3.7%. No participant experienced any severe or serious adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients with LUTS due to BPH, tamsulosin and tadalafil alone or in combination cause a significant improvement in patients with LUTS. Their EF also improves with these medications. The improvement is better with combination therapy compared with single agent alone.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jsm.12357","type":"journal-article","created":{"date-parts":[[2013,10,25]],"date-time":"2013-10-25T05:12:01Z","timestamp":1382677921000},"page":"187-196","source":"Crossref","is-referenced-by-count":57,"title":["A Comparative Randomized Prospective Study to Evaluate Efficacy and Safety of Combination of Tamsulosin and Tadalafil vs. Tamsulosin or Tadalafil Alone in Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia"],"prefix":"10.1093","volume":"11","author":[{"given":"Dig Vijay","family":"Singh","sequence":"first","affiliation":[{"name":"Department of Urology \u00a0 , Chandigarh , India"},{"name":"Post Graduate Institute of Medical Education & Research \u00a0 , Chandigarh , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uttam Kumar","family":"Mete","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , Chandigarh , India"},{"name":"Post Graduate Institute of Medical Education & Research \u00a0 , Chandigarh , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arup Kumar","family":"Mandal","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , Chandigarh , India"},{"name":"Post Graduate Institute of Medical Education & Research \u00a0 , Chandigarh , India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrawan Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Urology \u00a0 , Chandigarh , India"},{"name":"Post Graduate Institute of Medical Education & Research \u00a0 , Chandigarh , India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,1,1]]},"reference":[{"key":"2024032602362046400_bib1","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1743-6109.2006.00274.x","article-title":"How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia?","volume":"3","author":"Costabile","year":"2006","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib2","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-4295(02)02102-7","article-title":"Epidemiology of erectile dysfunction in four countries: Cross-national study of the prevalence and correlates of erectile dysfunction","volume":"61","author":"Nicolosi","year":"2003","journal-title":"Urology"},{"key":"2024032602362046400_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/sj.ijir.3900622","article-title":"Epidemiology of erectile dysfunction: Results of the \u201cCologne Male Survey\u201d","volume":"12","author":"Braun","year":"2000","journal-title":"Int J Impot Res"},{"key":"2024032602362046400_bib4","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1743-6109.2005.00132.x","article-title":"Lower urinary tract symptoms in patients with erectile dysfunction: Analysis of risk factors","volume":"3","author":"El-Sakka","year":"2006","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib5","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.urology.2004.01.039","article-title":"Obstructive lower urinary tract symptoms correlate with erectile dysfunction","volume":"63","author":"Elliott","year":"2004","journal-title":"Urology"},{"issue":"suppl 2","key":"2024032602362046400_bib6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1464-410X.2006.06102.x","article-title":"Lower urinary tract symptoms and sexual dysfunction: Epidemiology and pathophysiology","volume":"97","author":"McVary","year":"2006","journal-title":"BJU Int"},{"key":"2024032602362046400_bib7","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.juro.2006.10.055","article-title":"Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: A randomized, double-blind trial","volume":"177","author":"McVary","year":"2007","journal-title":"J Urol"},{"key":"2024032602362046400_bib8","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.juro.2006.11.037","article-title":"Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"177","author":"McVary","year":"2007","journal-title":"J Urol"},{"key":"2024032602362046400_bib9","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/j.1743-6109.2006.00259.x","article-title":"Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction","volume":"3","author":"Mulhall","year":"2006","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib10","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/jsm.12212","article-title":"Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: Analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies","volume":"10","author":"Porst","year":"2013","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib11","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1111\/j.1743-6109.2007.00754.x","article-title":"Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum","volume":"5","author":"Oger","year":"2008","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib12","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1016\/j.eururo.2007.01.033","article-title":"Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction","volume":"51","author":"Kaplan","year":"2007","journal-title":"Eur Urol"},{"key":"2024032602362046400_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.eururo.2004.05.008","article-title":"Efficacy and safety of long-term treatment with 5a-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia","volume":"46","author":"Debruyne","year":"2004","journal-title":"Eur Urol"},{"key":"2024032602362046400_bib14","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"2024032602362046400_bib15","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1743-6109.2005.00132.x","article-title":"Lower urinary tract symptoms in patients with erectile dysfunction: Analysis of risk factors","volume":"3","author":"Ahmed","year":"2006","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib16","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1111\/j.1743-6109.2007.00598.x","article-title":"Is the current practice providing an integrated approach to the management of LUTS and ED in primary care? An audit and literature review","volume":"4","author":"Chitale","year":"2007","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ju.0000078083.38675.79","article-title":"AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: Diagnosis and treatment recommendations","volume":"170","author":"AUA Practice Guidelines Committee","year":"2003","journal-title":"J Urol"},{"key":"2024032602362046400_bib18","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/j.1743-6109.2004.10104.x","article-title":"Summary of the recommendations on sexual dysfunctions in men","volume":"1","author":"Lue","year":"2004","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/jsm.12023","article-title":"SOP conservative (medical and mechanical) treatment of erectile dysfunction","volume":"10","author":"Porst","year":"2013","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib20","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1097\/01.ju.0000142687.75577.e4","article-title":"Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men","volume":"172","author":"Kloner","year":"2004","journal-title":"J Urol"},{"key":"2024032602362046400_bib21","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1161\/01.CIR.0000146906.42375.D3","article-title":"Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction","volume":"110","author":"Kloner","year":"2004","journal-title":"Circulation"},{"key":"2024032602362046400_bib22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/sj.ijir.3901490","article-title":"Phosphodiesterase type 5 inhibitors' extended duration of response as a variable in the treatment of erectile dysfunction","volume":"19","author":"Dunn","year":"2007","journal-title":"Int J Impot Res"},{"key":"2024032602362046400_bib23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.eururo.2009.04.033","article-title":"Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia","volume":"56","author":"Porst","year":"2009","journal-title":"Eur Urol"},{"key":"2024032602362046400_bib24","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1743-6109.04042.x","article-title":"Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil","volume":"1","author":"McMahon","year":"2004","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib25","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/S0022-5347(05)64442-4","article-title":"Efficacy and safety of tadalafil for the treatment of erectile dysfunction: Results of integrated analyses","volume":"168","author":"Brock","year":"2002","journal-title":"J Urol"},{"key":"2024032602362046400_bib26","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1111\/j.1743-6109.2008.00940.x","article-title":"Comparative efficacy assessment of tamsulosin vs. tamsulosin plus tadalafil in the treatment of LUTS\/BPH. Pilot study","volume":"5","author":"Bechara","year":"2008","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib27","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1111\/j.1743-6109.2008.00935.x","article-title":"Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction","volume":"5","author":"Porst","year":"2008","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib28","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1743-6109.2008.01109.x","article-title":"Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: An integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report","volume":"6","author":"Liguori","year":"2009","journal-title":"J Sex Med"},{"key":"2024032602362046400_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.ijir.3900815","article-title":"Combined oral therapy with sildenafil and doxazosin for the treatment of nonorganic erectile dysfunction refractory to sildenafil monotherapy","volume":"14","author":"De Rose","year":"2002","journal-title":"Int J Impot Res"},{"issue":"2 suppl","key":"2024032602362046400_bib30","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1464-410X.2006.06105.x","article-title":"Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: Treatments of lower urinary tract symptoms, erectile dysfunction, or both?","volume":"97","author":"Carson","year":"2006","journal-title":"BJU Int"},{"issue":"3 suppl","key":"2024032602362046400_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1464-410X.2008.07494.x","article-title":"Lower urinary tract symptoms and sexual dysfunction: A common approach","volume":"101","author":"Giuliano","year":"2008","journal-title":"BJU Int"},{"key":"2024032602362046400_bib32","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1111\/j.1743-6109.2012.02821.x","article-title":"Tadalafil enhances the inhibitory effects of tamsulosin on neurogenic contractions of human prostate and bladder neck","volume":"9","author":"Angulo","year":"2012","journal-title":"J Sex Med"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515305488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515305488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/11\/1\/187\/48359508\/jsm_11_1_187.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/11\/1\/187\/48359508\/jsm_11_1_187.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,25]],"date-time":"2024-03-25T23:10:46Z","timestamp":1711408246000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/11\/1\/187\/6958269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,1]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2014,1,1]]},"published-print":{"date-parts":[[2014,1,1]]}},"URL":"https:\/\/doi.org\/10.1111\/jsm.12357","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.718156967.793489989","asserted-by":"object"}]},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2014,1]]},"published":{"date-parts":[[2014,1,1]]}}}